{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.4","upperLimit":"47.6","value":"22.2"},{"groupId":"OG001","lowerLimit":"25.0","upperLimit":"43.8","value":"34.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Clinical benefit rate defined as percentage of participants who achieved minimal response (MR) or better. MR: \\>=25% but \\<= 49% reduction of serum M-protein and reduction in urine M-protein by 50%-89%. If present at baseline 25% to 49% reduction in size of soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity.","id":"OG000","title":"Daratumumab 8 mg/kg"},{"description":"Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity.","id":"OG001","title":"Daratumumab 16 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all participants who received at least 1 dose of daratumumab.","reportingStatus":"POSTED","timeFrame":"Up to 14.4 Months","title":"Percentage of Participants With Clinical Benefit","type":"SECONDARY","unitOfMeasure":"percentage of participants"}